findmyKOL
Clinical trialNCT00028990CompletedPhase 3Interventional

Paclitaxel With or Without Bevacizumab in Treating Patients With Locally Recurrent or Metastatic Breast Cancer

SponsorEastern Cooperative Oncology GroupEnrollment722Breast Cancer
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

RATIONALE: Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop tumor cells from dividing so they stop growing or die. Monoclonal antibodies, such as bevacizumab, can block cancer growth in different ways. Some block the ability of cancer cells to grow and spread. Others find cancer cells and help kill them or deliver cancer-killing substances to them. It is not yet known whether paclitaxel works better with or without bevacizumab in treating breast cancer. PURPOSE: This randomized phase III trial is to see if paclitaxel works better with or without bevacizumab in treating patients who have locally recurrent or metastatic breast cancer.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

30 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Canada
  • British Columbia Cancer Agency

    Vancouver, British Columbia, Canada

  • Allan Blair Cancer Centre

    Regina, Saskatchewan, Canada

United States
  • Mbccop - Gulf Coast

    Mobile, Alabama, United States

  • Ccop - Mayo Clinic Scottsdale Oncology Program

    Scottsdale, Arizona, United States

  • Mayo Clinic - Jacksonville

    Jacksonville, Florida, United States

  • Ccop - Atlanta Regional

    Atlanta, Georgia, United States

  • Ccop - Illinois Oncology Research Association

    Peoria, Illinois, United States

  • Ccop - Carle Cancer Center

    Urbana, Illinois, United States

  • Ccop - Cedar Rapids Oncology Project

    Cedar Rapids, Iowa, United States

  • Ccop - Iowa Oncology Research Association

    Des Moines, Iowa, United States

  • Siouxland Hematology-Oncology

    Sioux City, Iowa, United States

  • Ccop - Ochsner

    New Orleans, Louisiana, United States

  • Ccop - Michigan Cancer Research Consortium

    Ann Arbor, Michigan, United States

  • Ccop - Duluth

    Duluth, Minnesota, United States

  • Mayo Clinic Cancer Center

    Rochester, Minnesota, United States

  • Centracare Health Plaza

    Saint Cloud, Minnesota, United States

  • Ccop - Metro-Minnesota

    Saint Louis Park, Minnesota, United States

  • Ccop - Missouri Valley Cancer Consortium

    Omaha, Nebraska, United States

  • Medcenter One Health System

    Bismarck, North Dakota, United States

  • Ccop - Merit Care Hospital

    Fargo, North Dakota, United States

  • Altru Cancer Center

    Grand Forks, North Dakota, United States

  • Ccop - Dayton

    Dayton, Ohio, United States

  • Ccop - Toledo Community Hospital

    Toledo, Ohio, United States

  • Ccop - Oklahoma

    Tulsa, Oklahoma, United States

  • Ccop - Geisinger Clinic and Medical Center

    Danville, Pennsylvania, United States

  • Allegheny General Hospital

    Pittsburgh, Pennsylvania, United States

  • Ccop - Upstate Carolina

    Spartanburg, South Carolina, United States

  • Rapid City Regional Hospital

    Rapid City, South Dakota, United States

  • Ccop - Sioux Community Cancer Consortium

    Sioux Falls, South Dakota, United States

  • Ccop - St. Vincent Hospital Cancer Center, Green Bay

    Green Bay, Wisconsin, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Paclitaxel →Bevacizumab →
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
29 Jan 2002
Primary completion
30 Nov 2006
Completion
31 May 2009
Last update posted
15 Jun 2023
Registered enrollment
722
Registry id
NCT00028990
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.